Archived content

Day1  |  Day 2 |  Short CoursesDownload Brochure



12:30 pm Registration


2:00 Chairperson’s Opening Remarks

Reid Huber, Ph.D., Executive Director, Metabolic Endocrine Drug Development, Incyte Corporation

2:10 Modulating Lipid Metabolism

Cristina Rondinone, Ph.D., Director, Research, Metabolic Diseases, Roche Pharmaceuticals

2:40 FGF21 for Treatment of Metabolic Diseases

Jesper Gromada, Ph.D., Executive Director, Cardio-Vascular Metabolic Disease Area, Novartis Institutes for BioMedical Research

Fibroblast growth factor 21 (FGF21) is a potent metabolic regulator and a promising novel therapy for cardiovascular diseases, obesity and type 2 diabetes. In this talk I will review the preclinical pharmacology contributing to the actions of FGF21. A special emphasis will be placed on the molecular mechanisms by which FGF21 maintains energy homeostasis. In addition, knowledge gaps and challenges for further exploration of the therapeutic potential of this molecule will be addressed.

3:10 The Tipping Point between Life and Death of ER Stressed Pacreatic Beta Cells

Fumihiko Urano, M.D., Ph.D., Associate Professor of Molecular Medicine, University of Massachussetts Medical School


3:40 Networking Refreshment Break in the Exhibit Hall

4:20 Liver-directed Thyroid Beta Agonist for Targeting Cardio-metabolic Disease

Rebecca Taub, M.D., Senior Vice President, Research & Development, VIA Pharmaceuticals

VIA-3196, a liver-directed thyroid hormone beta agonist has the potential to provide benefit to patients with cardiometabolic risk including diabetics and dislipidemics. VIA-3196 lowers LDL cholesterol alone or in synergy with statins by greater than 40% in preclinical models, and reduces plasma triglicerides. VIA-3196 reduces hepatic triglicerides, a major cause of liver insulin resistance and non-alcoholic steatohepatitis. In animal models of diabetes and insulin reistance, VIA-3196 improves insulin sensitivity and lowers glucose to a similar level as rosiglitazone without causing weight gain.

4:50 Sponsored Presentation
(Sponsorship Opportunity Available)

5:20 Targeting the Gut for the Treatment of Metabolic Diseases

Andrew Swick, Ph.D., Senior Consultant, Illuminate BioPharma Consulting, LLC

5:50 Inhibiting Enterocytic MTP for Treatment of Diabetes and Metabolic Syndrome

Paul Sweetnam, Ph.D., Chief Scientific Officer, Surface Logix

SLx-4090 is a potent and selective small molecule inhibitor of microsomal triglyceride transfer protein (MTP). The compound was specifically designed to maximize therapeutic activity by targeting the enterocyte/intestinal wall while eliminating potential adverse effects associated with the inhibition of hepatic and/or cardiac MTP. Initial (2 week) clinical trials designed to explore the safety and effectiveness of this strategy indicated that SLx-4090 was well tolerated with no indication of LFT alterations. SLx-4090 was effective in reducing postprandial plasma triglycerides, chylomicrons and fasting LDL levels.    

6:20 Close of Day

Day1  |  Day 2 |  Short Courses 


Suggested Event Package (November 1 – 4):

November 1

Pre-Conference Short Courses:

Targeting GPCRs and Ion Channels with Antibodies (SC2)

November 2 - 3


Ion Channels as Therapeutic Targets OR GPCR-Based Drug Discovery

November 3 - 4


Targeting Diabetes with Novel Therapeutics